{"id":"W2735850899","doi":"10.1111/bjh.14829","title":"Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from <scp>ENEST</scp>xtnd","year":2017,"lang":"en","type":"article","venue":"British Journal of Haematology","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":22,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto","funders":"Novartis Pharmaceuticals Corporation","keywords":"Nilotinib; Medicine; Adverse effect; Rash; Internal medicine; Clinical endpoint; Nausea; Clinical trial; Oncology; Myeloid leukemia; Imatinib","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00295238,0.000504441,0.001045114,0.0001806362,0.000182174,0.0006153264,0.0004475135,0.0003563333,0.0006857835],"category_scores_gemma":[0.001709925,0.0001830921,0.0009690949,0.0002452235,0.0002885594,0.000285275,0.0003882599,0.001092511,0.0001857261],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001090355,"about_ca_system_score_gemma":0.00124382,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001433577,"about_ca_topic_score_gemma":0.004238682,"domain_scores_codex":[0.9991743,0.0004136697,0.00005219004,0.00009107306,0.0001597868,0.0001089763],"domain_scores_gemma":[0.998912,0.0002530965,0.0003222968,0.0001226348,0.0001116467,0.000278197],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2761624,0.03546276,0.07656839,0.0009245838,0.003015159,0.0007423425,0.0005743303,0.02494157,0.0905487,0.0007114319,0.01195849,0.4783898],"study_design_scores_gemma":[0.1720078,0.4565203,0.2943828,0.0001657229,0.001847652,0.001948951,0.0001592628,0.01150795,0.02823414,0.0006110661,0.03246925,0.0001451603],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939469,0.002204384,0.0005715447,0.0002533308,0.0000244599,0.0005233989,0.0009896606,0.00003869058,0.001447645],"genre_scores_gemma":[0.9897001,0.001519525,0.00240623,0.0004534555,0.00005404794,0.0004794078,0.004036656,0.00001921521,0.001331398],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.00295238,"threshold_uncertainty_score":0.01561385,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02974140965789916,"score_gpt":0.3104479218850639,"score_spread":0.2807065122271647,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}